2012/10/03 Taipei, Oct. 3, 2012 (CENS)--To realize the "Cross-Strait Agreement of Medicinal Product Cooperation Project", the Taiwan Food and Drug Administration (TFDA) under Department of Health (DOH) of the Executive Yuan recently commissioned the Center for Drug Evaluation (CDE) to set up a promotion office for the cross-strait cooperation scheme. At the office inauguration ceremony, Chiu Wen-ta, Minister of DOH, encouraged the new unit to help TFDA deal with future`s cross-strait affairs and help establish a cross-strait compunction and consulting platform for the biotechnology, pharmaceutical and medical device industries on the both sides of the Taiwan Strait. The office is expected to help companies on the two sides solve problems on pharmaceutical registration and commercialization. J.J. Kang, Director General of TFDA, said that he anticipated the CDE to utilize its accumulated capability in food and drug inspection, abundant experiences in consultancy and understanding of international regulations to further expand its services to the medicinal product industry. The establishment of the cross-strait cooperation promotion office, he added, is expected to more actively serve related industries, as well as collect information for TFDA, so as to achieve a win-win status for both Taiwan and China`s medicinal product industry. CDE`s CEO Kao Chuen-hsiu pointed out that the promotion office would provide more services to help makers know more about how to venture into the Chinese market during new drugs` R&D, clinical trial and registration stages.(by Quincy Liang)
No comments:
Post a Comment